NASDAQ : IMTX
Immatics N.V. — Key statistics
Healthcare · Biotechnology · Germany
Last price 7.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 984.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 965.03M |
| Enterprise Value | 532.33M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 136.69M |
| Shares Outstanding | 136.69M |
| Shares Change (YoY) | +11.50% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 3.45% |
| Owned by Institutions (%) | 42.06% |
| Float | 70.12M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.37 |
| Forward PS | 25.72 |
| PB Ratio | 2.16 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 11.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.54 |
| Quick Ratio | 7.02 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -261.27 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -47.80% |
| Return on Assets (ROA) | -26.92% |
| Return on Invested Capital (ROIC) | -1,086.06% |
| Return on Capital Employed (ROCE) | -52.89% |
| Weighted Average Cost of Capital (WACC) | 11.63% |
| Revenue Per Employee | $67,678 |
| Profits Per Employee | -$335,192 |
| Employee Count | 704 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -245,630 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -30.72% |
| 50-Day Moving Average | 8.21 |
| 200-Day Moving Average | 9.58 |
| Relative Strength Index (RSI) | 39.33 |
| Average Volume (20 Days) | 1,149,755 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.75M |
| Short Previous Month | 3.69M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 5.34% |
| Short Ratio (days to cover) | 4.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 47.65M |
| Gross Profit | -201.89M |
| Operating Income | -259.09M |
| Pretax Income | -236.22M |
| Net Income | -235.98M |
| EBITDA | -249.09M |
| EBIT | -259.09M |
| Loss Per Share | -$1.83 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 449.39M |
| Total Debt | 16.69M |
| Net Cash | 432.70M |
| Net Cash Per Share | $3.17 |
| Equity (Book Value) | 456.56M |
| Book Value Per Share | 3.34 |
| Working Capital | 425.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -230.67M |
| Capital Expenditures | -4.13M |
| Depreciation & Amortization | 9.81M |
| Net Borrowing | -3.33M |
| Free Cash Flow | -234.81M |
| FCF Per Share | -$1.72 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -543.79% |
| Pretax Margin | -495.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.50% |
| Shareholder Yield | -11.50% |
| Earnings Yield | -25.90% |
| FCF Yield | -24.19% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $16.40 |
| Price Target Difference | 132.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 27.90% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.94 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |